About: Cardiovascular disease management during the coronavirus disease 2019 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cardiovascular disease management during the coronavirus disease 2019 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cardiovascular disease management during the coronavirus disease 2019 pandemic
Creator	Chen, Chang-Jen Chen, Szu-Chia Chen, Ying-Chih Chu, Chun-Yuan Hsu, Po-Chao Kuo, Chao-Hung Lee, Chee-Siong Lee, Wen-Hsien Lin, Tsung-Hsien Su, Ho-Ming Tsai, Wei-Chung Voon, Wen-Chol
source	Medline; PMC
abstract	Based on clinical presentation, pathophysiology, high infectivity, high cardiovascular involvement, and therapeutic agents with cardiovascular toxicity of coronavirus disease 2019 (COVID-19), regular cardiovascular treatment is being changing greatly. Despite angiotensin-converting enzyme 2 serving as the portal for infection, the continuation of clinically indicated renin-angiotensin-aldosterone blockers is recommended according to the present evidence. Fibrinolytic therapy can be considered a reasonable option for the relatively stable ST segment elevation myocardial infarction (STEMI) patient with suspected or known COVID-19. However, primary percutaneous coronary intervention is still the standard of care in patients with definite STEMI if personal protective equipment is available and cardiac catheterization laboratory has a good infection control. In patients with elevated cardiac enzymes, it is very important to differentiate patients with Type 2 myocardial infarction or myocarditis from those with true acute coronary syndromes because invasive percutaneous intervention management in the former may be unnecessary, especially if they are hemodynamically stable. Finally, patients with baseline QT prolongation or those taking QT prolonging drugs must be cautious when treating with lopinavir/ritonavir and hydroxychloroquine for COVID-19.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.7150/ijms.46484
bibo:pmid	32624690
has license	cc-by
sha1sum (hex)	24752f3c61f09b0a24afbcd010a139856d4ff580
schema:url	https://doi.org/10.7150/ijms.46484
resource representing a document's title	Cardiovascular disease management during the coronavirus disease 2019 pandemic
has PubMed Central identifier	PMC7330658
has PubMed identifier	32624690
schema:publication	Int J Med Sci
resource representing a document's body	covid:24752f3c61f09b0a24afbcd010a139856d4ff580#body_text
is schema:about of	named entity 'percutaneous' named entity 'pathophysiology' named entity 'patients' named entity 'ST segment elevation' named entity 'cardiovascular toxicity' named entity 'high' named entity 'primary' named entity 'International Journal' named entity 'pandemic' named entity 'Medical Sciences' covid:arg/24752f3c61f09b0a24afbcd010a139856d4ff580 named entity 'presentation' named entity 'baseline' named entity 'definite' named entity 'high' named entity 'QT prolongation' named entity 'coronavirus disease 2019' named entity 'myocarditis' named entity 'patients' named entity 'blockers' named entity 'acute coronary syndromes' named entity 'hydroxychloroquine' named entity 'renin-angiotensin-aldosterone' named entity 'cardiac enzymes' named entity 'QT prolongation' named entity 'lopinavir/ritonavir' named entity 'myocardial infarction' named entity 'ST segment elevation myocardial infarction' named entity 'cardiac catheterization laboratory' named entity 'Type 2' named entity 'acute coronary syndromes' named entity 'cardiovascular' named entity 'infection control' named entity 'International Journal of Medical Sciences' named entity 'infection' named entity 'infection' named entity 'unstable angina' named entity 'World Health Organization' named entity 'COVID' named entity 'aldosterone' named entity '2, 3' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'palpitation' named entity 'COVID' named entity 'Type 2' named entity 'percutaneous coronary intervention' named entity 'COVID-19' named entity 'pneumonia' named entity 'China' named entity 'COVID-19' named entity 'SARS-CoV-2 virus' named entity 'renin-angiotensin-aldosterone' named entity 'receptor' named entity 'thrombolytic therapy' named entity 'coronary flow' named entity 'aminopeptidase' named entity 'ACE inhibitors' named entity 'intensive care unit' named entity 'angiotensin II' named entity 'percutaneous coronary intervention' named entity 'COVID' named entity 'COVID' named entity 'arrhythmia' named entity 'renin-angiotensin-aldosterone' named entity 'ACE2' named entity 'symptom' named entity 'standard of care' named entity 'comorbidities' named entity 'aldosterone'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software